Genetic information firm Invitae has partnered with genomic profiling company KEW to develop new comprehensive genomic profiling solutions so it can sequence tumour DNA on its next-generation sequencing (NGS) platform.
KEW’s new capabilities for somatic mutation detection will be integrated with Invitae’s diagnostic genetic testing panels, which were developed for hereditary cancers to enable better cancer care, from diagnosis until treatment.
Invitae’s germline testing analyses inherited genetic changes that enhance the risk of certain cancers, while KEW’s somatic testing evaluates acquired DNA alterations that can drive a tumour’s growth.
Invitae CEO Sean George said: “Broadening our ability to capture genetic information on both tumour biology and a patient’s inherited risk of disease while maintaining our commitment to lowering cost enhances Invitae’s ability to expand the market and enable affordable, high-quality precision care for more patients.”
KEW’s CancerPlex sequencing assay helps in detecting somatic mutations in 435 genes and allows assessment of tumour mutational burden and microsatellite instability to identify potential responders to immune checkpoint inhibitors.
Invitae will fund both the new development project and the integration of KEW’s technology into its platform and workflow.
As part of the deal, the company will have access to KEW’s bioinformatics software and the CancerPlex sequencing assay.
KEW president and CEO Jerry Williamson said: “State-of-the-art bioinformatics has enabled Invitae to build out a uniquely scalable offering well suited to rapid integration with our proprietary algorithms for optimal and accurate genomic variant detection and curated knowledge base.
“We believe aligning these capabilities on a single platform will provide the basis for making molecular characterisation the standard of care.”